VolitionRX Ltd. (VNRX) to Advance Blood-Based Diagnostics for Cancer
VolitonRX, a life sciences company focused on the development of diagnostic blood tests, is developing its Nucleosomics™ technology to measure and identify the signatures of nucleosomes (a protein component of a chromosome containing a short length of DNA) that are released into the blood as cells die. The company believes its pioneering technology will help detect early stage diseases that are characterized by high cell turnover, such as cancer. When a cell dies, individual nucleosomes are released into the blood to be recycled. It is well-known that high levels of nucleosomes are released into the blood stream as a result…